Newport Premium (for Generics)

Powerful integrated API intelligence with unique analysis

Newport Premium (for Generics) is the most advanced product targeting, global business development and API sourcing system from the industry authority on the global generics market.

Spot the right opportunity to get to market and get ahead.

Created specifically for demanding professionals in generic pharmaceutical companies, OTC and API manufacturers, *Newport Premium (for Generics)* can help you to identify and evaluate new product development and licensing opportunities ahead of the competition.

Unique strategic intelligence and powerful competitive analysis

Integrating intelligence on more than 140,000 launched products, 12,500 APIs and 66,000 corporate groups and subsidiary companies , the sophisticated targeting capabilities of *Newport Premium (for Generics)* can help you indentify promising new partner companies and secure early, exclusive sources of API supply.

Clarivate Analytics

API consumption data and trends can be included in product-targeting searches, enabling you to find the most appropriate business opportunities quickly and accurately.

Test and explore new business strategies, recognize potential barriers to market entry, and plan your development pipeline effectively. With the industry's most sophisticated product targeting capabilities, you can significantly enhance your competitive edge.

How you benefit

Strategic planning

- Evaluate new product development opportunities in over 70 markets worldwide including India and China.
- Identify niche opportunities that match your strategic needs and unique research, sales or marketing strengths.
- Adjust your research timing, priorities and resources based on active competitive intelligence monitoring.

Business development

- Profile competitors, business partners, and candidate products for acquisition, alliances, licensing, or supply and manufacturing.
- Track and monitor the launch, API development and patenting activities of competitors worldwide, including India and China.
- Evaluate candidate products against the earliest competitive intelligence.

API sourcing and sales

- Recognize critical patent, exclusivity and regulatory issues with candidate products.
- Analyze and compare API consumption data and trends by region, and by dose form for the current and previous year.
- Discover early, exclusive sources of API supply.
- Analyze routes of synthesis together with required intermediates and reagents, in addition to the referenced patents and scientific literature.



atorvastatin calcium

atorvastatin calcium	Sales (in $USD) 12 mo Ending	12 mo Ending	% Change	Consumption in kg 12 mo Ending	12 mo Ending	% Change
ask ims — All	*31 Dec 2016*	*31 Dec 2015*		*31 Dec 2016*	*31 Dec 2015*	
USA:	817.4M	919.8M	-11.1%	146,435.7 kg	125,280.3 kg	16.9%
EU Top 5:	1037.9M	922.3M	12.5%	111,511.4 kg	96,571 kg	15.5%
Rest of Europe:	521.1M	501.7M	3.9%	79,418.2 kg	71,229.6 kg	11.5%
Latin America:	567.1M	490.1M	15.7%	14,066.6 kg	13,563.7 kg	3.7%
Rest of World:	2495.9M	2472.9M	.9%	142,920.2 kg	131,421.6 kg	8.7%
Worldwide:	5439.3M	5306.9M	2.5%	494,352.1 kg	438,066.3 kg	12.8%

First US Approval Date (NDA):	17 Dec 1996
First Marketing Authorization in Europe available to Newport:	07 Nov 1996 (UK)
First Marketing Authorization in EEA available to Newport:	07 Nov 1996 (UK)
EphMRA Therapeutic Index:	Lipid-regulating/anti-atheroma preparations; Non-Narcotics And Anti-Pyretics; Lipid-regulating cardiovascular multitherapy fixed combination products; Statins (HMG-CoA reductase inhibitors)
US DEA Schedules:	
Technologies:	Drug combination; Small molecule therapeutic; Systemic formulation unspecified
CAS Number:	134523-03-8

Newport Analysis

API Availability Rating: No Confirmed Sources … Excessively Available

Excessively Available

Product profile pages summarize all key product-related data, from sales to exclusivities

Broad, trusted global industry data

Consolidated data on generics

- Patent expiration
- Paragraph IV data
- Patent constraints
- Market size
- Sales volume, consumption and pricing
- Market leads for potential partners/ acquisition targets
- Region-specific data
- Competitor intelligence

Product intelligence

- Market size and sales volume data
- Unique, early API manufacturing intelligence for 12,500 active ingredients
- Regulatory filings, such as US, Japanese and Korean DMFs, Certificates of Suitability, Indian and Chinese Import Registrations and US DEA registration notices
- Two years of regional sales and consumption data, worldwide launch, and pack price data for 140,000 products, 360,000 trade names and 12,500 APIs
- US Orange Book, EU centralized procedure, and European first market authorization data
- Worldwide manufacturer labels
- Global finished dose approval data
- Chemical structure diagrams for thousands of products
- Routes of synthesis, including intermediates and reagents with patent and literature references for over 3,000 products
- Powerful indexing and searching of products according to FDA approved indication and technology class
- Proprietary analytics
- GMP Certifications by Brazil, China, India, Mexico, WHO and many other countries
- US GDUFA DMF Reference Status, Facility Registrations and Facility Fee payment

Company intelligence

- Competitor profiles of over 66,000 groups and subsidiary companies finished dose launches, US approvals, regulatory filings, APIs manufactured, inspections by the US FDA and other regulatory agencies and Warning Letters
- Detailed manufacturing capabilities for 600 API and biologic manufacturing sites
- Company key financial indicators and sales forecasts
- Proprietary company ratings

Patents

- Worldwide patent families and individual patents for more than 90 countries
- Comprehensive Supplementary Protection Certificate (SPC) data for Europe
- Projected loss of exclusivity dates for US, European, Australian, Canadian, Japanese and South Korean markets
- Paragraph IV patent challenges commentaries, including company identities, FTF and status of litigation for more than 500 products

Current awareness

- E-mail alerting on key changes in products and companies, including new regulatory filings, approvals, and patent challenges
- Reports on key conferences of interest to the generics and API industries

To learn more about *Newport Premium (for Generics)*, including the additional modules for Phase III Drugs, Generic Industry Deals (including mergers and acquisitions), US Market Share, and Biologics, visit **clarivate.com/newport-premium**

Who we are

Clarivate Analytics accelerates the pace of innovation by providing trusted insights and analytics to customers around the world, enabling them to discover, protect and commercialize new ideas faster. We own and operate a collection of leading subscription-based services focused on scientific and academic research, patent analytics and regulatory standards, pharmaceutical and biotech intelligence, trademark protection, domain brand protection and intellectual property management. *Clarivate Analytics* is now an independent company with over 4,000 employees, operating in more than 100 countries and owns well-known brands that include *Web of Science*, *Cortellis*, *Derwent*, *CompuMark*, *MarkMonitor* and *Techstreet*, among others. For more information, visit: clarivate.com

For more information:
clarivate.com/newport-premium

North America
Philadelphia: +1 800 336 4474
+1 215 386 0100

Latin America
Brazil: +55 11 8370 9845
Other countries: +1 215 823 5674

Europe, Middle East and Africa
London: +44 20 7433 4000

Asia Pacific
Singapore: +65 6775 5088
Tokyo: +81 3 5218 6500

clarivate.com

06.2017

Clarivate Analytics